Concepts (299)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 23 | 2017 | 312 | 2.420 |
Why?
|
| Cognition | 20 | 2019 | 526 | 2.060 |
Why?
|
| Growth Hormone-Releasing Hormone | 4 | 2018 | 7 | 1.180 |
Why?
|
| Insulin | 12 | 2015 | 346 | 1.060 |
Why?
|
| Neuropsychological Tests | 22 | 2019 | 379 | 1.060 |
Why?
|
| Postmenopause | 7 | 2019 | 397 | 1.050 |
Why?
|
| Exercise | 8 | 2019 | 591 | 0.960 |
Why?
|
| Hormones | 2 | 2013 | 19 | 0.900 |
Why?
|
| Cognition Disorders | 8 | 2013 | 390 | 0.900 |
Why?
|
| Glucose | 4 | 2013 | 163 | 0.860 |
Why?
|
| Insulin Resistance | 7 | 2019 | 449 | 0.850 |
Why?
|
| Aged | 48 | 2019 | 9487 | 0.800 |
Why?
|
| Exercise Therapy | 3 | 2019 | 229 | 0.760 |
Why?
|
| Peptide Fragments | 8 | 2018 | 422 | 0.720 |
Why?
|
| Cacao | 1 | 2019 | 4 | 0.710 |
Why?
|
| Estradiol | 3 | 2011 | 118 | 0.690 |
Why?
|
| Aged, 80 and over | 26 | 2019 | 3717 | 0.690 |
Why?
|
| Double-Blind Method | 16 | 2019 | 501 | 0.690 |
Why?
|
| Female | 53 | 2019 | 18164 | 0.690 |
Why?
|
| Hypovolemia | 1 | 2018 | 3 | 0.680 |
Why?
|
| Vitamins | 1 | 2019 | 58 | 0.680 |
Why?
|
| Phlebotomy | 1 | 2018 | 17 | 0.680 |
Why?
|
| Plant Extracts | 1 | 2019 | 60 | 0.670 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 45 | 0.670 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 32 | 0.670 |
Why?
|
| Hepatectomy | 1 | 2018 | 66 | 0.650 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2019 | 1379 | 0.640 |
Why?
|
| Dietary Supplements | 1 | 2019 | 170 | 0.630 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 5 | 2019 | 48 | 0.630 |
Why?
|
| Humans | 61 | 2019 | 29093 | 0.600 |
Why?
|
| Brain | 7 | 2017 | 930 | 0.600 |
Why?
|
| Male | 46 | 2019 | 17807 | 0.590 |
Why?
|
| Middle Aged | 31 | 2019 | 10829 | 0.560 |
Why?
|
| Memory | 8 | 2018 | 187 | 0.550 |
Why?
|
| Apolipoprotein E4 | 9 | 2015 | 58 | 0.550 |
Why?
|
| Hypoglycemic Agents | 6 | 2015 | 176 | 0.520 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 2108 | 0.490 |
Why?
|
| Aging | 5 | 2013 | 881 | 0.480 |
Why?
|
| Sleep | 5 | 2019 | 86 | 0.440 |
Why?
|
| Osteoarthritis | 4 | 2014 | 74 | 0.440 |
Why?
|
| Glucose Intolerance | 2 | 2010 | 44 | 0.430 |
Why?
|
| Estrogens | 2 | 2011 | 162 | 0.420 |
Why?
|
| Diet, Fat-Restricted | 1 | 2012 | 30 | 0.420 |
Why?
|
| Life Style | 5 | 2018 | 364 | 0.400 |
Why?
|
| Hydrocortisone | 1 | 2011 | 61 | 0.400 |
Why?
|
| Executive Function | 5 | 2019 | 54 | 0.390 |
Why?
|
| Prediabetic State | 1 | 2010 | 54 | 0.370 |
Why?
|
| Physical Fitness | 2 | 2010 | 119 | 0.360 |
Why?
|
| Motor Activity | 1 | 2012 | 310 | 0.350 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 141 | 0.350 |
Why?
|
| Lipid Metabolism | 3 | 2015 | 100 | 0.340 |
Why?
|
| Dementia | 5 | 2019 | 234 | 0.320 |
Why?
|
| Overweight | 4 | 2018 | 256 | 0.310 |
Why?
|
| Time Factors | 7 | 2019 | 2001 | 0.300 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2011 | 182 | 0.300 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2012 | 80 | 0.290 |
Why?
|
| Treatment Outcome | 15 | 2019 | 3099 | 0.290 |
Why?
|
| Hormone Replacement Therapy | 2 | 2017 | 86 | 0.280 |
Why?
|
| Affect | 3 | 2012 | 63 | 0.230 |
Why?
|
| Caloric Restriction | 2 | 2019 | 92 | 0.200 |
Why?
|
| Longitudinal Studies | 7 | 2019 | 720 | 0.200 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 129 | 0.200 |
Why?
|
| Analysis of Variance | 5 | 2015 | 454 | 0.200 |
Why?
|
| Sulfonamides | 3 | 2011 | 65 | 0.200 |
Why?
|
| Obesity | 5 | 2019 | 1063 | 0.190 |
Why?
|
| Diet | 2 | 2013 | 354 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 71 | 0.180 |
Why?
|
| Risk Factors | 4 | 2018 | 3531 | 0.180 |
Why?
|
| Problem Solving | 2 | 2018 | 27 | 0.180 |
Why?
|
| Genotype | 5 | 2013 | 735 | 0.180 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 4 | 0.170 |
Why?
|
| Amnesia | 2 | 2011 | 10 | 0.170 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 22 | 0.170 |
Why?
|
| Colorectal Surgery | 1 | 2018 | 2 | 0.170 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2017 | 125 | 0.170 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 24 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2018 | 51 | 0.170 |
Why?
|
| Cohort Studies | 7 | 2018 | 1687 | 0.170 |
Why?
|
| Heart Rate | 2 | 2010 | 315 | 0.160 |
Why?
|
| Dietary Fats | 2 | 2015 | 108 | 0.150 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 162 | 0.150 |
Why?
|
| Nootropic Agents | 1 | 2017 | 13 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 464 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3111 | 0.150 |
Why?
|
| Decision Making | 1 | 2018 | 180 | 0.140 |
Why?
|
| West Nile Fever | 1 | 2016 | 1 | 0.140 |
Why?
|
| West Nile virus | 1 | 2016 | 1 | 0.140 |
Why?
|
| Glucose Tolerance Test | 2 | 2015 | 125 | 0.140 |
Why?
|
| Behavior Therapy | 1 | 2017 | 89 | 0.140 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 172 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 208 | 0.140 |
Why?
|
| Polysomnography | 1 | 2016 | 32 | 0.140 |
Why?
|
| Apolipoproteins E | 5 | 2014 | 97 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 355 | 0.140 |
Why?
|
| Retinal Diseases | 1 | 2016 | 18 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 37 | 0.140 |
Why?
|
| Memory Disorders | 2 | 2008 | 61 | 0.140 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 47 | 0.140 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 69 | 0.130 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2015 | 3 | 0.130 |
Why?
|
| Insulin, Long-Acting | 1 | 2015 | 3 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2015 | 42 | 0.130 |
Why?
|
| Research Design | 2 | 2014 | 286 | 0.130 |
Why?
|
| Primary Health Care | 2 | 2014 | 178 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2018 | 859 | 0.130 |
Why?
|
| Body Mass Index | 5 | 2019 | 865 | 0.130 |
Why?
|
| Pain | 2 | 2014 | 282 | 0.130 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 37 | 0.130 |
Why?
|
| Cerebellar Diseases | 1 | 2014 | 4 | 0.130 |
Why?
|
| Cerebellar Cortex | 1 | 2014 | 4 | 0.130 |
Why?
|
| Laminin | 1 | 2014 | 13 | 0.130 |
Why?
|
| Naproxen | 2 | 2011 | 8 | 0.130 |
Why?
|
| Amyloid | 1 | 2014 | 17 | 0.130 |
Why?
|
| Cysts | 1 | 2014 | 16 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 91 | 0.120 |
Why?
|
| Sex Characteristics | 2 | 2013 | 167 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2011 | 64 | 0.120 |
Why?
|
| Fatigue | 1 | 2014 | 68 | 0.120 |
Why?
|
| Exercise Test | 2 | 2016 | 194 | 0.120 |
Why?
|
| Mental Status Schedule | 4 | 2017 | 24 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2011 | 56 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 641 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2018 | 670 | 0.120 |
Why?
|
| Arthralgia | 1 | 2013 | 31 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2018 | 1305 | 0.110 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 74 | 0.110 |
Why?
|
| Administration, Intranasal | 4 | 2015 | 30 | 0.110 |
Why?
|
| Patient Selection | 1 | 2014 | 257 | 0.110 |
Why?
|
| Psychotherapy, Group | 1 | 2012 | 15 | 0.110 |
Why?
|
| Mental Recall | 3 | 2015 | 52 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2013 | 119 | 0.110 |
Why?
|
| Prevalence | 4 | 2019 | 896 | 0.100 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 21 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 20 | 0.100 |
Why?
|
| Neuropeptides | 1 | 2011 | 19 | 0.100 |
Why?
|
| Food, Formulated | 1 | 2011 | 10 | 0.100 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 21 | 0.100 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 26 | 0.100 |
Why?
|
| Severity of Illness Index | 4 | 2012 | 863 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2013 | 223 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 116 | 0.100 |
Why?
|
| Energy Metabolism | 2 | 2010 | 139 | 0.100 |
Why?
|
| Body Composition | 1 | 2012 | 365 | 0.100 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 94 | 0.090 |
Why?
|
| Blood Pressure | 1 | 2014 | 804 | 0.090 |
Why?
|
| Thromboxane B2 | 1 | 2010 | 6 | 0.090 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2010 | 3 | 0.090 |
Why?
|
| Glucose Clamp Technique | 1 | 2010 | 12 | 0.090 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 34 | 0.090 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 36 | 0.090 |
Why?
|
| Brain Chemistry | 2 | 2013 | 30 | 0.090 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 36 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 92 | 0.090 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 251 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 59 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2011 | 181 | 0.090 |
Why?
|
| tau Proteins | 3 | 2017 | 38 | 0.090 |
Why?
|
| Octreotide | 1 | 2009 | 3 | 0.090 |
Why?
|
| Gastrointestinal Agents | 1 | 2009 | 6 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 138 | 0.090 |
Why?
|
| Somatostatin | 1 | 2009 | 10 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 110 | 0.080 |
Why?
|
| Norepinephrine | 2 | 2006 | 73 | 0.080 |
Why?
|
| Verbal Behavior | 1 | 2008 | 9 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 126 | 0.080 |
Why?
|
| Administration, Cutaneous | 2 | 2011 | 107 | 0.080 |
Why?
|
| Cloprostenol | 1 | 2007 | 1 | 0.080 |
Why?
|
| Thiazines | 1 | 2007 | 1 | 0.080 |
Why?
|
| Exfoliation Syndrome | 1 | 2007 | 1 | 0.080 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2007 | 2 | 0.080 |
Why?
|
| Ocular Hypertension | 1 | 2007 | 6 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2007 | 13 | 0.080 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2007 | 17 | 0.080 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2007 | 41 | 0.080 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 59 | 0.070 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2006 | 17 | 0.070 |
Why?
|
| Organ Size | 2 | 2017 | 196 | 0.070 |
Why?
|
| Hyperinsulinism | 1 | 2005 | 12 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2018 | 2019 | 0.070 |
Why?
|
| Health Status | 2 | 2019 | 368 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2005 | 47 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2019 | 274 | 0.070 |
Why?
|
| Activities of Daily Living | 2 | 2017 | 238 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2015 | 85 | 0.060 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2004 | 3 | 0.060 |
Why?
|
| Aptitude | 1 | 2004 | 2 | 0.060 |
Why?
|
| Cytokines | 1 | 2005 | 243 | 0.060 |
Why?
|
| Automobile Driving | 1 | 2004 | 24 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2003 | 7 | 0.060 |
Why?
|
| Alleles | 2 | 2014 | 251 | 0.060 |
Why?
|
| Triglycerides | 1 | 2004 | 214 | 0.060 |
Why?
|
| Adult | 5 | 2016 | 8420 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1013 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 246 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 507 | 0.050 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 20 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 1356 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 89 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2013 | 364 | 0.050 |
Why?
|
| United States | 3 | 2016 | 3630 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 1218 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2019 | 8 | 0.040 |
Why?
|
| Attention | 2 | 2014 | 83 | 0.040 |
Why?
|
| Indians, North American | 1 | 2019 | 108 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 48 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1108 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 441 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 2402 | 0.040 |
Why?
|
| Synaptotagmins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Synaptophysin | 1 | 2018 | 2 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 447 | 0.040 |
Why?
|
| F2-Isoprostanes | 2 | 2010 | 20 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 273 | 0.040 |
Why?
|
| Animals | 4 | 2015 | 7297 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2018 | 110 | 0.040 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 532 | 0.040 |
Why?
|
| Exosomes | 1 | 2018 | 38 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2011 | 469 | 0.040 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2017 | 89 | 0.040 |
Why?
|
| Disease Progression | 1 | 2019 | 572 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2017 | 249 | 0.040 |
Why?
|
| Oximetry | 1 | 2016 | 28 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 726 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 163 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 427 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2015 | 10 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2015 | 14 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1119 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2015 | 32 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 35 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2015 | 37 | 0.030 |
Why?
|
| Psychomotor Disorders | 1 | 2015 | 4 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 263 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 160 | 0.030 |
Why?
|
| Space Perception | 1 | 2015 | 26 | 0.030 |
Why?
|
| Radiography | 1 | 2016 | 353 | 0.030 |
Why?
|
| Muscular Dystrophies | 1 | 2014 | 4 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 137 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2014 | 25 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 32 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2368 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1362 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 139 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 240 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 425 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2014 | 82 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 413 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 130 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 525 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 33 | 0.030 |
Why?
|
| Cholesterol | 1 | 2015 | 229 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2013 | 45 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 80 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 128 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 23 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 787 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2006 | 466 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2012 | 95 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 29 | 0.030 |
Why?
|
| Immunoassay | 1 | 2011 | 11 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2011 | 20 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 33 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 980 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2011 | 140 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 290 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 1167 | 0.020 |
Why?
|
| Aspirin | 1 | 2010 | 61 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 127 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 709 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2009 | 47 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 3254 | 0.020 |
Why?
|
| Child | 1 | 2014 | 2219 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2007 | 25 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 43 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 366 | 0.020 |
Why?
|
| Japan | 1 | 2006 | 15 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 73 | 0.020 |
Why?
|
| Prealbumin | 1 | 2005 | 8 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2005 | 33 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2005 | 45 | 0.020 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2006 | 110 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2005 | 225 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 200 | 0.020 |
Why?
|
| Ketone Bodies | 1 | 2004 | 6 | 0.020 |
Why?
|
| Mental Competency | 1 | 2004 | 5 | 0.020 |
Why?
|
| Language | 1 | 2004 | 44 | 0.010 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2003 | 6 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 57 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 76 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 97 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2004 | 97 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 121 | 0.010 |
Why?
|
| Prostate | 1 | 2003 | 68 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2003 | 138 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 449 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 519 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 95 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 298 | 0.010 |
Why?
|